The studies concluded that the CDA test is useful for cancer screening with high specificity and moderate sensitivity among healthy individuals and continues to lay both the conceptual and ...

AnPac Bio had previously completed more than 169,000 CDA-based tests as of March 31, 2020. From April 1, 2020 to July 15, 2020, the Company completed over 10,000 commercial CDA-based tests and ...

AnPac Bio’s follow-up study involved (a) enrolling high, medium, and low risk groups of individuals based on their CDA test scores following CDA testing of a large, asymptomatic population, (b ...

The above-mentioned Class III medical device designation is based on AnPac Bio’s novel cancer differentiation analysis (CDA) technology, which has been used in cancer risk assessment tests for ...